var data={"title":"Infliximab (including biosimilars of infliximab): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Infliximab (including biosimilars of infliximab): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6369?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Infliximab (including biosimilars of infliximab): Patient drug information&quot;</a> and <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Infliximab (including biosimilars of infliximab): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708921\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients treated with infliximab are at an increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Discontinue infliximab if a patient develops a serious infection or sepsis.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Reported infections include the following:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before infliximab use and during therapy. Treatment for latent infection should be initiated prior to infliximab use.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk of invasive fungal infections who develop severe systemic illness.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Bacterial, viral, and other infections caused by opportunistic pathogens, including <i>Legionella</i> and <i>Listeria</i>.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The risks and benefits of treatment with infliximab should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with infliximab, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab. These cases have had a very aggressive disease course and have been fatal. Almost all patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. The majority of reported infliximab cases have occurred in patients with Crohn disease or ulcerative colitis, and most were in adolescent and young adult males.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182756\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Inflectra;</li>\n      <li>Remicade;</li>\n      <li>Renflexis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182757\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Inflectra;</li>\n      <li>Remicade;</li>\n      <li>Remsima</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182785\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antirheumatic, Disease Modifying;</li>\n      <li>\n        Gastrointestinal Agent, Miscellaneous;</li>\n      <li>\n        Immunosuppressant Agent;</li>\n      <li>\n        Monoclonal Antibody;</li>\n      <li>\n        Tumor Necrosis Factor (TNF) Blocking Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182760\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premedication with antihistamines (H<sub>1</sub>-antagonist +/- H<sub>2</sub>-antagonist), acetaminophen, and/or corticosteroids may be considered to prevent and/or manage infusion-related reactions. Renflexis, Inflectra, Ixifi, and Remsima [Canadian product] are approved as biosimilar to Remicade. Approved uses for biosimilar agents may vary (consult product labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ankylosing spondylitis:</b> IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 6 weeks thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease:</b> IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter; dose may be increased to 10 mg/kg in patients who respond but then lose their response. If no response by week 14, consider discontinuing therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plaque psoriasis:</b> IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriatic arthritis (with or without methotrexate):</b> IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis (in combination with methotrexate therapy):</b> IV 3 mg/kg at 0, 2, and 6 weeks, followed by 3 mg/kg every 8 weeks thereafter; Remicade doses have ranged from 3 to 10 mg/kg repeated at 4- to 8-week intervals</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis:</b> IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter. Doses up to 10 mg/kg were studied in clinical trials with similar efficacy observed with both doses (Rutgeerts 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pustular psoriasis (off-label use):</b> IV: 5 mg/kg at week 0, 2, and 6, followed by 5 mg/kg every 8 weeks for up to 46 weeks (Suguira 2014; Torii 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment with heart failure (HF):</b> Weigh risk versus benefits for individual patient:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mild HF (NYHA Class I/II): </i>No dosage adjustment necessary; use with caution and monitor closely for worsening of HF</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate to severe (NYHA Class III or IV):</i> &le;5 mg/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182775\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Infliximab (including biosimilars of infliximab): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premedication with antihistamines (H<sub>1</sub>-antagonist +/- H<sub>2</sub>-antagonist), acetaminophen, and/or corticosteroids may be considered to prevent and/or manage infusion-related reactions. Renflexis, Inflectra, Ixifi, and Remsima [Canadian product] are approved as biosimilar to Remicade. Approved uses for biosimilar agents may vary (consult product labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease:</b> Children &ge;6 years and Adolescents: IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter; in adult patients with Crohn disease, it has been observed that patients who do not respond by week 14 are unlikely to respond with continued dosing; consider discontinuing therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis:</b> Children &ge;6 years and Adolescents: IV (Remicade only): 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Juvenile idiopathic arthritis (off-label use):</b> Children &ge;4 years and Adolescents: IV: Initial: 3 mg/kg at 0, 2, and 6 weeks; then 3 to 6 mg/kg/dose every 8 weeks thereafter, in combination with methotrexate during induction and maintenance (Ruperto 2010). Alternatively, some studies used 6 mg/kg starting at week 14 of a methotrexate induction regimen (weeks 0 to 13); repeat dose (6 mg/kg) at week 16 and 20, then every 8 weeks thereafter (Ruperto 2007; Visvanathan 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182761\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182762\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182763\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182738\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Inflectra: infliximab-dyyb 100 mg (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Remicade: 100 mg (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renflexis: infliximab-abda 100 mg (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182723\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27749143\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infliximab-abda (Renflexis), infliximab-dyyb (Inflectra), infliximab-qbtx (Ixifi), and Remsima [Canadian product] are approved as biosimilar to Remicade.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Remicade contains sucrose 500 mg per vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27649635\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Reconstituted, Intravenous (preservative free):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Remicade: 100 mg (contains polysorbate 80, sucrose 500 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inflectra: 100 mg (contains polysorbate 80, sucrose 500 mg; biosimilar agent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Remsima 100 mg (contains polysorbate 80, sucrose 500 mg; biosimilar agent)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50858894\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Ixifi (infliximab-qbtx): FDA approved December 2017; anticipated availability is currently undetermined.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874621\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Remicade: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103772s5377lbl.pdf#page=48&amp;token=w+qfyl11AzX2CakqwTlx0ziep+obGMs6Bk9ShPxDKLr+/pftg0T4o6ffHP4942rEtky0b8h78dAJluZ1uerKH2WQD+eb7UX3pdHk6y70R0/t4feAzTBW9N/w+Y6A+Owl&amp;TOPIC_ID=8984\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103772s5377lbl.pdf#page=48</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inflectra: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM497384.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274gi3LbMdiQvFNuvjB+hSaKSgw==&amp;TOPIC_ID=8984\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM497384.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renflexis (infliximab-abda): <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM497384.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274gi3LbMdiQvFNuvjB+hSaKSgw==&amp;TOPIC_ID=8984\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761054lbl.pdf#page=51</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182740\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: The infusion should begin within 3 hours of reconstitution and dilution. Infuse over at least 2 hours; do not infuse with other agents; use in-line low protein binding filter (&le;1.2 micron). Temporarily discontinue or decrease infusion rate with infusion-related reactions. Antihistamines (H<sub>1</sub>-antagonist +/- H<sub>2</sub>-antagonist), acetaminophen and/or corticosteroids may be used to manage reactions. Infusion may be reinitiated at a lower rate upon resolution of mild to moderate symptoms.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Guidelines for the treatment and prophylaxis of infusion reactions:</b> (<b>Note:</b> Limited to adult patients and dosages used in Crohn disease; prospective data for other populations [pediatrics, other indications/dosing] are not available).</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">A protocol for the treatment of infusion reactions, as well as prophylactic therapy for repeat infusions, has been published (Mayer, 2006).</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">\n      <i>Treatment of infusion reactions:</i> Medications for the treatment of hypersensitivity reactions should be available for immediate use. For mild reactions, the rate of infusion should be decreased to 10 mL/hour. Initiate a normal saline infusion (500 to 1,000 mL/hour) and appropriate symptomatic treatment (eg, acetaminophen and diphenhydramine); monitor vital signs every 10 minutes until normal. After 20 minutes, the infusion may be increased at 15-minute intervals, as tolerated, to completion (initial increase to 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc [maximum of 125 mL/hour]). For moderate reactions, the infusion should be stopped or slowed. Initiate a normal saline infusion (500 to 1,000 mL/hour) and appropriate symptomatic treatment. Monitor vital signs every 5 minutes until normal. After 20 minutes, the infusion may be reinstituted at 10 mL/hour; then increased at 15-minute intervals, as tolerated, to completion (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc [maximum of 125 mL/hour]). For severe reactions, the infusion should be stopped with administration of appropriate symptomatic treatment (eg, hydrocortisone/methylprednisolone, diphenhydramine and epinephrine) and frequent monitoring of vitals (consult institutional policies, if available). Re-treatment after a severe reaction should only be done if the benefits outweigh the risks and with appropriate prophylaxis. Delayed infusion reactions typically occur 1 to 7 days after an infusion. Treatment should consist of appropriate symptomatic treatment (eg, acetaminophen, antihistamine, methylprednisolone).</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">\n      <i>Prophylaxis of infusion reactions:</i> Premedication with acetaminophen and diphenhydramine 90 minutes prior to infusion may be considered in all patients with prior infusion reactions, and in patients with severe reactions corticosteroid administration is recommended. Steroid dosing may be oral (prednisone 50 mg orally every 12 hours for 3 doses prior to infusion) or intravenous (a single dose of hydrocortisone 100 mg or methylprednisolone 20 to 40 mg administered 20 minutes prior to the infusion). On initiation of the infusion, begin with a test dose at 10 mL/hour for 15 minutes. Thereafter, the infusion may be increased at 15-minute intervals, as tolerated, to completion (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc). A maximum rate of 125 mL/hour is recommended in patients who experienced prior mild to moderate reactions and 100 mL/hour is recommended in patients who experienced prior severe reactions. In patients with cutaneous flushing, aspirin may be considered (Becker, 2004). For delayed infusion reactions, premedicate with acetaminophen and diphenhydramine 90 minutes prior to infusion. On initiation of the infusion, begin with a test dose at 10 mL/hour for 15 minutes. Thereafter, the infusion may be increased to infuse over 3 hours. Postinfusion therapy with acetaminophen for 3 days and an antihistamine for 7 days is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182739\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ankylosing spondylitis:</b> Treatment of adults with active ankylosing spondylitis (to reduce signs/symptoms)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease:</b> Treatment of adults and pediatric patients &ge;6 years with moderately to severely active Crohn disease who have had inadequate responses to conventional therapy (to reduce signs/symptoms and induce and maintain clinical remission) or to reduce the number of draining enterocutaneous and rectovaginal fistulas and maintain fistula closure in adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plaque psoriasis:</b> Treatment of adults with chronic, severe (extensive and/or disabling) plaque psoriasis as an alternative to other systemic therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriatic arthritis:</b> Treatment of adults with psoriatic arthritis (to reduce signs/symptoms of active arthritis and inhibit progression of structural damage and improve physical function)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b> Treatment of adults with moderately to severely active rheumatoid arthritis (with methotrexate) (to reduce signs/symptoms of active arthritis and inhibit progression of structural damage and improve physical function)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis:</b> Treatment of adults and pediatric patients &ge;6 years (Remicade only) with moderately to severely active ulcerative colitis with inadequate response to conventional therapy (to reduce signs/symptoms and induce and maintain clinical remission and mucosal healing and eliminate corticosteroid use)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> Renflexis, Inflectra, Ixifi, and Remsima [Canadian product] are approved as biosimilar to Remicade; approved uses may vary (see product labeling).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25882047\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Juvenile idiopathic arthritis; Beh&ccedil;et syndrome uveitis; Pustular psoriasis; Pyoderma gangrenosum</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182793\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">InFLIXimab may be confused with idaruCIZUmab, riTUXimab</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Remicade may be confused with Renacidin, Rituxan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182730\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (Crohn disease: 26%; rheumatoid arthritis: 12%), nausea (21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (adults: &lt;1%; children and adolescents with Crohn disease: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&lt;3 x ULN: 17% to 51%; &ge;3 x ULN: 2% to 10%; &ge; 5x ULN: 1% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Increased ANA titer (~50%), antibody development (double-stranded DNA, ~20%), antibody development (6% to 15%; more immunogenic when given as a single induction dose, episodic treatment, and monotherapy; Mayer 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (adults with Crohn disease: 50% ; children and adolescents with Crohn disease: 38% to 74%; other indications: 27% to 59%), serious infection (5%; children and adolescents: 12% to 60%), abscess (Crohn disease patients with fistulizing disease: 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (rheumatoid arthritis: 32%; children and adolescents with ulcerative colitis: 12%), sinusitis (14%), cough (12%), pharyngitis (8% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion related reaction (&le;18%; severe: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (children and adolescents with Crohn disease: 9%), hypertension (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (9%), pain (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (10%), pruritus (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (children and adolescents with Crohn disease: 9%; other indications: &lt;1%), neutropenia (children and adolescents with Crohn disease: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (children and adolescents with Crohn disease: 6%; other indications: &lt;1%), delayed hypersensitivity (plaque psoriasis: 1%), serum sickness (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Viral infection (children and adolescents with Crohn disease: 8%), bacterial infection (children and adolescents with Crohn disease: 6%), candidiasis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (8%), bone fracture (children and adolescents with Crohn disease: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (10%), pneumonia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute hepatic failure, agranulocytosis, anaphylaxis, autoimmune hepatitis, bradycardia, bronchospasm, cardiac arrhythmia, cellulitis, cerebrovascular accident, cholestasis, chronic inflammatory demyelinating polyneuropathy, coccidioidomycosis, constipation, cytomegalovirus disease, dehydration, demyelinating disease of the central nervous system, demyelinating disease (peripheral), dermal ulcer, diaphoresis, dizziness, edema, erythema multiforme, erythematous rash, exacerbation of psoriasis, Guillain-Barre syndrome, hemolytic anemia, hepatic failure, hepatic injury, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hepatosplenic T-cell lymphomas (mainly young adult or adolescent males), herpes zoster, histoplasmosis, Hodgkin lymphoma, hypotension, immune thrombocytopenia, increased serum AST, interstitial pulmonary disease, intestinal obstruction, ischemic heart disease, jaundice, laryngeal edema, leukemia, liver enzyme disorder (transient), lower respiratory tract infection, lupus-like syndrome, lymphadenopathy, malignant lymphoma, malignant melanoma, malignant neoplasm, malignant neoplasm of breast, malignant neoplasm of cervix, malignant neoplasm of colon or rectum, Merkel cell carcinoma, multiple sclerosis, myocardial infarction, neuropathy (includes multifocal motor), nocardiosis, non-Hodgkin lymphoma, opportunistic infection, optic neuritis, pancytopenia, pericardial effusion, pharyngeal edema, pleurisy, pneumocystosis, psoriasis (including new onset, palmoplantar, pustular), pulmonary edema, pulmonary fibrosis, reactivated tuberculosis, reactivation of HBV, sarcoidosis, seizure, sepsis, Stevens-Johnson syndrome, thrombocytopenia, thrombophlebitis, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis, transverse myelitis, tuberculosis, urticaria, vasculitis (systemic and cutaneous), temporary vision loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182743\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to infliximab, murine proteins, or any component of the formulation; doses &gt;5 mg/kg in patients with moderate or severe heart failure (NYHA Class III/IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe infections (eg, sepsis, abscesses, tuberculosis, and opportunistic infections); use in patients with moderate or severe heart failure (NYHA Class III/IV)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182727\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome, have been reported; monitor and discontinue if symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular/cerebrovascular reactions during and following infusion: Cerebrovascular accidents, MI (some fatal), hypotension, hypertension, and arrhythmias have been reported within 24 hours of infusion. Transient vision loss has also been reported during or within 2 hours of infusion. Discontinue therapy if serious reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic disorders: Hematologic toxicities (eg, leukopenia, neutropenia, thrombocytopenia, pancytopenia) have been reported (may be fatal). Patients must be advised to seek medical attention if they develop signs and symptoms suggestive of blood dyscrasias (eg, persistent fevers); discontinue if significant hematologic abnormalities are confirmed. Use with caution in patients with history of hematologic abnormalities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic reactions: Severe hepatic reactions (including hepatitis, jaundice, acute hepatic failure, and cholestasis) have been reported during treatment; reactions occurred between 2 weeks to &gt;1 year after initiation of therapy and some cases were fatal or necessitated liver transplantation; discontinue with jaundice and/or marked increase in liver enzymes (&ge;5 times ULN).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B: Reactivation of hepatitis B virus (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants (may be fatal); evaluate for HBV prior to initiation in all patients. Monitor during and for several months following discontinuation of treatment in HBV carriers; interrupt therapy if reactivation occurs and treat appropriately with antiviral therapy; if resumption of therapy is deemed necessary, exercise caution and monitor patient closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity or infusion reactions: Acute infusion reactions may occur. Hypersensitivity reactions, including anaphylaxis, may occur within 2 hours of infusion. Medication and equipment for management of hypersensitivity reaction should be available for immediate use. Interruptions and/or reinstitution at a slower rate may be required (consult protocols). Pretreatment may be considered, and may be warranted in all patients with prior infusion reactions. Serum sickness-like reactions have occurred; may be associated with a decreased response to treatment. The development of antibodies to infliximab may increase the risk of hypersensitivity and/or infusion reactions; concomitant use of immunosuppressants may lessen the development of anti-infliximab antibodies. The risk of infusion reactions may be increased with re-treatment after an interruption or discontinuation of prior maintenance therapy. Re-treatment in psoriasis patients should be resumed as a scheduled maintenance regimen without any induction doses; use of an induction regimen should be used cautiously for re-treatment of all other patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Patients receiving infliximab are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate or corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (or reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral or other opportunistic infections (including legionellosis and listeriosis) have been reported. Monitor closely for signs/symptoms of infection. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to use in patients with a history of chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infection and develop severe systemic illness.</b> Caution should be exercised when considering use in the elderly or in patients with conditions that predispose them to infections (eg, diabetes) or residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent or localized infections. Do not initiate infliximab therapy in patients with an active infection, including clinically important localized infection. Patients who develop a new infection while undergoing treatment should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Lymphoma and other malignancies (may be fatal) have been reported in children and adolescent patients receiving TNF-blocking agents including infliximab.</b> Half the cases are lymphomas (Hodgkin's and non-Hodgkin's) and the other cases are varied but include malignancies not typically observed in this population. <b>[US Boxed Warning]: Postmarketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with infliximab. Almost all patients had received concurrent or prior treatment with azathioprine or mercaptopurine at or prior to diagnosis and the majority of reported cases occurred in adolescent and young adult males with Crohn disease or ulcerative colitis.</b> Malignancies occurred after a median of 30 months (range: 1 to 84 months) after the first dose of TNF blocker therapy; most patients were receiving concomitant immunosuppressants. The impact of infliximab on the development and course of malignancies is not fully defined. As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma. Use caution in patients with a history of COPD, higher rates of malignancy were reported in COPD patients treated with infliximab. Psoriasis patients with a history of phototherapy had a higher incidence of nonmelanoma skin cancers. Melanoma and Merkel cell carcinoma have been reported in patients receiving TNF-blocking agents including infliximab. Perform periodic skin examinations in all patients during therapy, particularly those at increased risk for skin cancer. Women with rheumatoid arthritis had a higher incidence of invasive cervical cancer; periodic screening should be continued in women treated with infliximab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: <b>[US Boxed Warning]: Infliximab treatment has been associated with active tuberculosis (may be disseminated or extrapulmonary) or reactivation of latent infections. Evaluate patients for tuberculosis risk factors and latent tuberculosis infection (with a tuberculin skin test) prior to and during therapy. Treatment of latent tuberculosis should be initiated before use. Patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis throughout treatment.</b> Most cases of reactivation have been reported within the first couple months of treatment. Caution should be exercised when considering the use in patients who have been exposed to tuberculosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Demyelinating CNS disease: Use with caution in patients with preexisting or recent onset CNS demyelinating disorders; rare cases of optic neuritis and demyelinating disease (including multiple sclerosis, systemic vasculitis, and Guillain-Barr&eacute; syndrome) have been reported; consider discontinuation of therapy if patient develops significant CNS reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure (HF): Use with caution in patients with mild HF (NYHA Class I, II) or decreased left ventricular function; worsening and new-onset HF has been reported; doses &gt;5 mg/kg should not be administered in patients with moderate to severe HF (NYHA Class III/IV); discontinue therapy with onset of new or worsening symptoms. In a scientific statement from the American Heart Association, TNF blockers have been determined to be agents that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizures; discontinue if significant CNS adverse reactions develop.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Malignancies have been reported among children and adolescents receiving TNF-blocking agents. Efficacy was not established in a study to evaluate infliximab use in juvenile idiopathic arthritis (JIA).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy. A fatal outcome has been reported in an infant who received a live vaccine (BCG) after in utero exposure to infliximab; infliximab crosses the placenta and has been detected in infants&rsquo; serum for up to 6 months. It is recommended to wait &ge;6 months following birth before administering any live vaccine to infants exposed to infliximab in utero.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299517\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182732\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8984&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adalimumab: May enhance the immunosuppressive effect of InFLIXimab.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: InFLIXimab may enhance the adverse/toxic effect of AzaTHIOprine. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. InFLIXimab may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etanercept: May enhance the immunosuppressive effect of InFLIXimab.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Golimumab: May enhance the immunosuppressive effect of InFLIXimab.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ustekinumab: May enhance the immunosuppressive effect of InFLIXimab.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182734\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182745\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted. Infliximab crosses the placenta and can be detected in the serum of infants for up to 6 months following in utero exposure. Agranulocytosis has been reported in infants exposed to infliximab in utero. A fatal outcome has been reported in an infant who received a live vaccine (BCG) after in utero exposure to infliximab; it is recommended to wait &ge;6 months following birth before administering any live vaccine to infants exposed to infliximab in utero. If a biologic agent such as infliximab is needed to treat inflammatory bowel disease during pregnancy, it is recommended to hold therapy after 30 weeks gestation (Habal 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are also encouraged to enroll women exposed to infliximab during pregnancy in the MotherToBaby Autoimmune Diseases Study by contacting the Organization of Teratology Information Specialists (OTIS) (877-311-8972).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182746\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Small amounts of infliximab are present in breast milk. Information is available from three postpartum women who were administered infliximab 5 mg/kg 1 to 24 weeks after delivery. Infliximab was detected within 12 hours and the highest milk concentrations (0.09 to 0.105 mcg/mL) were seen 2 to 3 days after the dose. Corresponding maternal serum concentrations were 18 to 64 mcg/mL (Ben-Horin 2011). Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182736\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor improvement of symptoms and physical function assessments. During infusion, if reaction is noted, monitor vital signs every 2 to 10 minutes, depending on reaction severity, until normal. If a serious reaction occurs (eg, cardiovascular or cerebrovascular reaction), discontinue the infusion. Active and latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; LFTs (discontinue if &gt;5 times ULN); signs and symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Psoriasis patients with history of phototherapy should be monitored for nonmelanoma skin cancer. Women should be screened periodically for cervical cancer.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The American Gastroenterological Association suggests reactive therapeutic drug monitoring to guide treatment changes in adult patients treated with infliximab for active inflammatory bowel disease (Feuerstein 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182726\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Infliximab is a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha (TNF&alpha;), thereby interfering with endogenous TNF&alpha; activity. Elevated TNF&alpha; levels have been found in involved tissues/fluids of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn disease and ulcerative colitis. Biological activities of TNF&alpha; include the induction of proinflammatory cytokines (interleukins), enhancement of leukocyte migration, activation of neutrophils and eosinophils, and the induction of acute phase reactants and tissue degrading enzymes. Animal models have shown TNF&alpha; expression causes polyarthritis, and infliximab can prevent disease as well as allow diseased joints to heal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182742\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Pharmacokinetic data in pediatric patients (6 to 17 years) reported to be similar to adult values.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Crohn disease: 1 to 2 weeks; Rheumatoid arthritis: 3 to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: Crohn disease: 8 to 48 weeks; Rheumatoid arthritis: 6 to 12 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Within the vascular compartment;  V<sub>d</sub>: 3 to 6 L (Klotz 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 7 to 12 days (Klotz 2007) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4370699\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Inflectra Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $1,135.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Remicade Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $1,401.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Renflexis Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $904.07</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182747\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Flixabi (IE);</li>\n      <li>Inflectra (CY, CZ, DE, DK, EE, ES, FI, FR, GB, HR, IE, IS, LT, LU, LV, MT, NL, NO, PT, RO, SE, SK, TR);</li>\n      <li>Reemsima (EE);</li>\n      <li>Remicade (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, UY, VE, VN);</li>\n      <li>Remmicade (LB);</li>\n      <li>Remsima (CY, CZ, DE, DK, ES, FI, FR, GB, HR, IE, IS, KR, LK, LT, LU, LV, MT, MY, NL, NO, PL, PT, RO, SE, SG, SK, TH, TR);</li>\n      <li>Remykeyd (UA);</li>\n      <li>Revellex (ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antoni CE, Kavanaugh A, Kirkham B, et al, &ldquo;Sustained Benefits of Infliximab Therapy for Dermatologic and Articular Manifestations of Psoriatic Arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT),&rdquo; <i>Arthritis Rheum</i>, 2005, 52(4):1227-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/15818699/pubmed\" target=\"_blank\" id=\"15818699\">15818699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Becker M, Rose CD, and McIlvain-Simpson G, &ldquo;Niacin-Like Reaction to Infliximab Infusion in Systemic Juvenile Rheumatoid Arthritis,&rdquo; <i>J Rheumatol</i>, 2004, 31(12):2529-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/15570667/pubmed\" target=\"_blank\" id=\"15570667\">15570667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. <i>J Crohns Colitis</i>. 2011;5(6):555-558.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/22115374/pubmed\" target=\"_blank\" id=\"22115374\">22115374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bongartz T, Sutton AJ, Sweeting MJ, et al, &ldquo;Anti-TNF Antibody Therapy In Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-Analysis of Rare Harmful Effects in Randomized Controlled Trials,&rdquo; <i>JAMA</i>, 2006, 295(19):2275-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/16705109/pubmed\" target=\"_blank\" id=\"16705109\">16705109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buch MH, Bryer D, Lindsay S, et al, &ldquo;Shortening Infusion Times for Infliximab Administration,&rdquo; <i>Rheumatology (Oxford)</i>, 2006, 45(4):485-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/16352636/pubmed\" target=\"_blank\" id=\"16352636\">16352636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carpenter PA and Sanders JE, &ldquo;Steroid-Refractory Graft-vs-Host Disease: Past, Present and Future,&rdquo; <i>Pediatr Transplant.</i> 2003, 7(Suppl 3):19-31.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control, &ldquo;Testing and Treatment of Latent Tuberculosis Infection,&rdquo; <i>MMWR Recomm Rep</i>, 2000, 49(RR-6).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung ES, Packer M, Lo KH, et al, &ldquo;Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-Alpha, in Patients with Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) Trial,&rdquo; <i>Circulation</i>, 2003, 107(25):3133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/12796126/pubmed\" target=\"_blank\" id=\"12796126\">12796126</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Couriel D, Saliba R, Hicks K, et al, &ldquo;Tumor Necrosis Factor-Alpha Blockade for the Treatment of Acute GVHD,&rdquo; <i>Blood</i>, 2004, 104(3):649-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/15069017/pubmed\" target=\"_blank\" id=\"15069017\">15069017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-&alpha; biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. <i>Gastroenterology</i>. 2013;145(6):1464-1478.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/24267475 /pubmed\" target=\"_blank\" id=\"24267475 \">24267475 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention,&rdquo; <i>Am J Respir Crit Care Med</i>, 2000, 161:1376-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/10764337/pubmed\" target=\"_blank\" id=\"10764337\">10764337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dommasch E and Gelfand JM, &ldquo;Is There Truly a Risk of Lymphoma From Biologic Therapies?&rdquo; <i>Dermatol Ther</i>, 2009, 22 (5):418-30.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. <i>Gastroenterology.</i> 2017;153(3):827-834. doi: 10.1053/j.gastro.2017.07.032.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/28780013/pubmed\" target=\"_blank\" id=\"28780013\">28780013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerloni V, Pontikaki I, Gattinara M, et al, &ldquo;Efficacy of Repeated Intravenous Infusions of an Anti-Tumor Necrosis Factor Alpha Monoclonal Antibody, Infliximab, in Persistently Active, Refractory Juvenile Idiopathic Arthritis,&rdquo; <i>Arthritis Rheum</i>, 2005, 52(2):548-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/15693004/pubmed\" target=\"_blank\" id=\"15693004\">15693004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. <i>Aliment Pharmacol Ther</i>. 2012;35(5):501-515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/22221203/pubmed\" target=\"_blank\" id=\"22221203\">22221203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ikeda R, Vermeulen LC, Lau E, Jiang Z, Saha S, Reichelderfer M, Kolesar JM. Stability of infliximab in polyvinyl chloride bags. <i>Am J Health Syst Pharm</i>. 2012;69(17):1509-1512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/22899746/pubmed\" target=\"_blank\" id=\"22899746\">22899746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inflectra (infliximab-dyyb) [prescribing information]. New York, NY: Pfizer; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inflectra (infliximab) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ixifi (infliximab-qbtx) [prescribing information]. New York, NY: Pfizer; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25473247\"></a>Kim HS, You HS, Cho HH, et al. Two cases of generalized pustular psoriasis: successful treatment with infliximab. <i>Ann Dermatol</i>. 2014;26(6):787-788.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/25473247/pubmed\" target=\"_blank\" id=\"25473247\">25473247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klotz U, Teml A, and Schwab M, &ldquo;Clinical Pharmacokinetics and Use of Infliximab,&rdquo; <i>Clin Pharmacokinet</i>, 2007, 45(8):645-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/17655372/pubmed\" target=\"_blank\" id=\"17655372\">17655372</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kornbluth A and Sachar DB, &ldquo;Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,&rdquo; <i>Am J Gastroenterol</i>, 2010, 105(3):501-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/20068560/pubmed\" target=\"_blank\" id=\"20068560\">20068560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo; <i>Am J Gastroenterol</i>, 2009, 104(2):465-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/19174807/pubmed\" target=\"_blank\" id=\"19174807\">19174807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, &ldquo;Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,&rdquo; <i>JAMA</i>, 2012, 308(9): 898-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/22948700/pubmed\" target=\"_blank\" id=\"22948700\">22948700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mayer L and Young Y, &ldquo;Infusion Reactions and Their Management,&rdquo; <i>Gastroenterol Clin North Am</i>, 2006, 35(4):857-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/17129817/pubmed\" target=\"_blank\" id=\"17129817\">17129817</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parakkal D, Sifuentes H, Semer R, et al, &ldquo;Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-&alpha; Inhibitor Therapy: Expanding the Groups at Risk,&rdquo; <i>Eur J Gastroenterol Hepatol</i>, 2011, 23(12):1150-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/21941193/pubmed\" target=\"_blank\" id=\"21941193\">21941193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Remicade (infliximab) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Remsima (infliximab) [product monograph]. Kirkland, Quebec, Canada: Hospira Healthcare Corporation; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Renflexis (infliximab) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Renflexis (infliximab) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ringold S, Weiss PF, Beukelman T, et al; American College of Rheumatology. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. <i>Arthritis Rheum</i>. 2013;65(10):2499-2512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/24092554/pubmed\" target=\"_blank\" id=\"24092554\">24092554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22609220\"></a>Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. <i>J Am Acad Dermatol</i>. 2012;67(2):279-288.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/22609220/pubmed\" target=\"_blank\" id=\"22609220\">22609220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17763439\"></a>Ruperto N, Lovell DJ, Cuttica R, et al, &ldquo;A Randomized, Placebo-Controlled Trial of Infliximab Plus Methotrexate for the Treatment of Polyarticular-Course Juvenile Rheumatoid Arthritis,&rdquo; <i>Arthritis Rheum</i>, 2007, 56(9):3096-106.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/17763439/pubmed\" target=\"_blank\" id=\"17763439\">17763439</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20237125\"></a>Ruperto N, Lovell DJ, Cuttica R, et al; Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension [published correction appears in <i>Ann Rheum Dis</i>. 2011;70(11):2060 and <i>Ann Rheum Dis</i>. 2012;71(6):1106]. <i>Ann Rheum Dis</i>. 2010;69(4):718-722.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/20237125/pubmed\" target=\"_blank\" id=\"20237125\">20237125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. <i>N Engl J Med</i>. 2005;353(23):2462-2476.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/16339095/pubmed\" target=\"_blank\" id=\"16339095\">16339095</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shergy WJ, Isern RA, Cooley DA, et al, &ldquo;Open Label Study to Assess Infliximab Safety and Timing of Onset of Clinical Benefit among Patients With Rheumatoid Arthritis,&rdquo; <i>J Rheumatol</i>, 2002, 29(4):667-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/11950005/pubmed\" target=\"_blank\" id=\"11950005\">11950005</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(5):625-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/22473917/pubmed\" target=\"_blank\" id=\"22473917\">22473917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23680215\"></a>Smith N, Harms KL, Hines AC, et al. Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab. <i>J Am Acad Dermatol</i>. 2013;68(6):e187-e189.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/23680215/pubmed\" target=\"_blank\" id=\"23680215\">23680215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24910924\"></a>Sugiura K, Endo K, Akasaka T, Akiyama M. Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist [published online ahead of print June 9, 2014]. <i>J Eur Acad Dermatol Venereol</i>. doi:10.1111/jdv.12590.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/24910924/pubmed\" target=\"_blank\" id=\"24910924\">24910924</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thayu M, Markowitz JE, Mamula P, et al, &ldquo;Hepatosplenic T-Cell Lymphoma in an Adolescent Patient After Immunomodulator and Biologic Therapy for Crohn Disease,&rdquo; <i>J Pediatr Gastroenterol Nutr</i>, 2005, 40(2):220-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/15699701/pubmed\" target=\"_blank\" id=\"15699701\">15699701</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-&alpha; biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. <i>Gastroenterology</i>. 2013;145(6):1459-1463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/24267474/pubmed\" target=\"_blank\" id=\"24267474\">24267474</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21544940\"></a>Torii H, Nakagawa H; Japanese Infliximab Study Investigators. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. <i>J Dermatol</i>. 2011;38(4):321-334.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/21544940/pubmed\" target=\"_blank\" id=\"21544940\">21544940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16091999\"></a>Trent JT, Kerdel FA. Successful treatment of Von Zumbusch pustular psoriasis with infliximab. <i>J Cutan Med Surg</i>. 2004;8(4):224-228.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/16091999/pubmed\" target=\"_blank\" id=\"16091999\">16091999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Vollenhoven RF, Gullstrom E, and Klareskog L, &ldquo;Feasibility of 1 Hour Infliximab Infusions,&rdquo; <i>Ann Rheum Dis</i>, 2005, 64(4):654.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/15769930/pubmed\" target=\"_blank\" id=\"15769930\">15769930</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247492\"></a>Viguier M, Aubin F, Delaporte E, et al; Groupe de Recherche sur le Psoriasis de la Soci&eacute;t&eacute; Fran&ccedil;aise de Dermatologie. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. <i>Arch Dermatol</i>. 2012;148(12):1423-1425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/23247492/pubmed\" target=\"_blank\" id=\"23247492\">23247492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20822542\"></a>Visvanathan S, Wagner C, Marini JC, et al; Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. <i>Pediatr Rheumatol Online J</i>. 2010;8:24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-drug-information/abstract-text/20822542/pubmed\" target=\"_blank\" id=\"20822542\">20822542</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8984 Version 171.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708921\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F182756\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F182757\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F182785\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F182760\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F182775\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F182761\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F182762\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F182763\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F182738\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F182723\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F27749143\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F27649635\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50858894\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874621\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F182740\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F182739\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25882047\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F182793\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F182730\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F182743\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F182727\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299517\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F182732\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F182734\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F182745\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F182746\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F182736\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F182726\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F182742\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F4370699\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F182747\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8984|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-patient-drug-information\" class=\"drug drug_patient\">Infliximab (including biosimilars of infliximab): Patient drug information</a></li><li><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-pediatric-drug-information\" class=\"drug drug_pediatric\">Infliximab (including biosimilars of infliximab): Pediatric drug information</a></li></ul></div></div>","javascript":null}